Merck KGaA : CMD feedback – Showing optimism for 2024
>Moving back to growth – Reiterated 2025 targets - Compared to last year, the key message has clearly shifted from resilience to growth. While 2023 has been transitional for Life Sciences and Electronics, Healthcare is performing very well. The mid-term growth targets were confirmed on a segmental level as well on group level with expected revenues of € 25bn in 2025, which we rate as positive. Our forecast stands at € 23.9bn, consensus at € 24.1bn. The overall feedbac...Merck is a global science and technology company based in Germany. Co. diversifies its activities into four business divisions: Merck Serono, Consumer Health, Performance Materials and Merck Millipore. The Merck Serono develops, manufactures and markets prescription drugs to treat cancer, multiple sclerosis, infertility, growth disorders, and selected cardiovascular and metabolic diseases. The Consumer Health manufactures and markets over-the-counter drugs addressing health themes such as mobility, women's and children's health, cough and cold. Performance Materials is a specialty chemicals business. The Merck Millipore is the supplier of products and services for the life science industry.
Oddo Securities provides securities brokerage and research services. The company offers equity, economic, and derivatives research and credit analysis services. It focuses on insurance, automotive, building materials, pharmaceuticals, telecommunications, information technology, and agri-food industries.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.